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Abstract
Recently, we demonstrated that osteoblast-specific overexpression of human WNT16 increased 
both cortical and trabecular bone mass and structure in mice. To further identify the cell-specific 
role of Wnt16 in bone homeostasis, we created transgenic (TG) mice over-expressing human 
WNT16 in osteocytes using Dmp1 promoter (Dmp1-hWNT16 TG) on C57BL/6 (B6) background. 
We analyzed bone phenotypes and serum bone biomarkers, performed gene expression analysis 
and measured dynamic bone histomorphometry in Dmp1-hWNT16 TG and wild-type (WT) mice. 
Compared to WT mice, Dmp1-hWNT16 TG mice exhibited significantly higher whole body, spine 
and femoral aBMD, BMC and trabecular (BV/TV, Tb.N, and Tb.Th) and cortical (bone area and 
thickness) parameters in both male and female at 12 weeks of age. Femur stiffness and ultimate 
force were also significantly improved in the Dmp1-hWNT16 TG female mice, compared to sex-
matched WT littermates. In addition, female Dmp1-hWNT16 TG mice displayed significantly 
higher MS/BS, MAR and BFR/BS compared to the WT mice. Gene expression analysis 
demonstrated significantly higher mRNA level of Alp in both male and female Dmp1-hWNT16 
TG mice and significantly higher levels of Osteocalcin, Opg and Rankl in the male Dmp1-
hWNT16 TG mice in bone tissue compared to sex-matched WT mice. These results indicate that 
WNT16 plays a critical role for acquisition of both cortical and trabecular bone mass and strength. 
Strategies designed to use WNT16 as a target for therapeutic interventions will be valuable to treat 
osteoporosis and other low bone mass conditions.
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Introduction
Currently, two major therapeutic approaches are available for the treatment of osteoporosis – 
anabolic and anti-resorptive therapies. While most pharmacological interventions for 
osteoporosis are targeted to prevent bone resorption, there is only one anabolic therapy 
(teriparatide or recombinant human parathyroid hormone, analog 1–34 or PTH) currently 
approved by the FDA aimed at enhancing bone formation (1, 2). However, PTH can be used 
for a period of only 2 years and needs to be followed by an anti-resorptive drug to preserve 
bone gain. Also, PTH is contra-indicated in children and patients with a history of skeletal 
malignancy or Paget’s disease (1, 2). Thus, discovery of novel molecules that will enhance 
bone formation and sustain positive bone balance at clinically relevant fracture sites are 
needed for the prevention and treatment of osteoporosis and other low bone mass conditions.
Previously, several genome-wide association studies (GWAS) identified common variants in 
genes in the WNT (Wingless-type mouse mammary tumor virus integration site) signaling 
pathway associated with bone mineral density (BMD) and risk of fracture (3–6). In addition, 
multiple GWAS studies demonstrated that genetic variations in WNT16 are associated with 
BMD and risk of fracture in children and adults across multiple populations (7–10). WNT16 
was also found to be associated with bone phenotypes at skeletal sites predominantly 
affected by osteoporotic fractures (8, 9). Recently, we identified SNPs in WNT16 were 
associated with peak BMD in premenopausal women (11). The overwhelming evidence 
from these human GWAS studies for potential regulation of bone homeostasis by WNT16 
was further strengthened by the development of animal models with either deletion of 
Wnt16 globally or conditionally in bone cells (7, 8, 12, 13). Specifically, global Wnt16 
knockout mice exhibited significantly lower cortical bone density and strength as well as 
increased susceptibility to fracture (8, 13), and these mice failed to increase periosteal bone 
formation in response to mechanical loading (12). Similarly, osteoblast-specific conditional 
Wnt16 knockout mice displayed decreased bone density, strength and increased porosity, 
particularly in the cortical bone (13). Together, these results suggest that WNT16 is critical 
for maintaining bone mass and strength, and that this molecule might be an attractive target 
for pharmacologic intervention in treating osteoporosis or other low bone mass conditions.
To further identify the role of WNT16 in bone biology, recently, we created transgenic mice 
overexpressing human WNT16 in osteoblast, and demonstrated that the transgenic mice 
displayed increased cortical and trabecular bone mass and structure in both growing and 
adult age, with robust trabecular phenotype particularly in female mice (14). Further, using 
transgenic mice overexpressing mouse Wnt16 in osteoblasts, Movérare-Skrtic S. et al, 
showed that the transgene had a robust effect on trabecular bone phenotype in adult female 
mice (15). These results suggest that WNT16 play significant role for acquisition and 
maintenance of trabecular bone mass in addition to its critical role for cortical bone mass 
regulation.
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The source and target cells of Wnt16 in skeletal tissue are currently mostly unknown. 
Therefore, we determined the expression of Wnt16 mRNA in bone cells (osteoblasts, 
osteocytes and osteoclasts) derived from primary culture. We detected significantly higher 
expression of Wnt16 in both osteoblasts (~300 fold) and osteocytes (~30 fold) compared to 
osteoclasts. Further, Movérare-Skrtic S. et al., showed that substantially lowered Wnt16 
mRNA expression in late osteoblasts and osteocytes led to significantly lower cortical bone 
thickness in elderly mice (13), suggesting that Wnt16 derived from osteocytes might play an 
important role in maintenance of bone mass during aging. To further identify the osteocyte-
specific role of WNT16 in bone homeostasis, we created transgenic (TG) mice that over-
express human WNT16 in late osteoblasts and osteocytes using Dmp1 (Dentin matrix 
protein 1) promoter (Dmp1-hWNT16) on C57BL/6 (B6) background. We measured bone 
density, structure and strength, evaluated serum biomarkers of bone metabolism, performed 
gene expression analyses and dynamic bone histomorphometry, and analyzed cellular 
parameters using both male and female Dmp1-hWNT16 TG and wild-type (WT) mice. We 
demonstrate that WNT16 overexpression in osteocytes influences trabecular and cortical 
bone mass, structure and strength in mice.
Materials and Methods
Generation of the Dmp1-hWNT16 transgenic mice
The cDNA of human WNT16 (IMAGE clone ID 8143948) cloned into the pCR4-TOPO 
vector, was obtained from Open Biosystem (PA, USA). The WNT16 gene was excised from 
this vector by EcoR1 digestion and was cloned into the pBluescript II KS plasmid (pBS-KS) 
from Agilent Technologies (CA, USA), inserted into the multiple cloning sites between the 
late osteoblast and osteocyte-specific Dmp1 promoter (8 kb of the 5’-flanking region, the 
first exon, the first intron and 17 bp of exon2 of the murine Dmp1 gene, a kind gift from 
Teresita Bellido) and rabbit beta-globin polyA signal (Figure 1A). The transgene expression 
construct (Dmp1 promoter + WNT16 cDNA + polyA tail sequence) was digested with NotI 
and SalI and microinjected into pronuclei of B6 fertilized eggs, which were then transferred 
into C57BL/6 (B6) foster mothers by the Indiana University Institutional Transgenic Animal 
Facility. The integration of the transgene(s) into the genome of founder mice was determined 
by PCR using tail DNA.
Experimental Animals
We used 10 male and 10 female mice per genotype (Dmp1-hWNT16 TG and wild-type 
littermates as controls) in this study unless stated specifically otherwise. All mice were 
generated and maintained at Indiana University. Mice were housed in polycarbonate cages in 
a vivarium maintained on a 12-h light and 12-h dark cycle and were fed a regular diet and 
water ad libitum. The procedures performed throughout the experiment were in accordance 
with the ethical standards and guidelines of the Indiana University Animal Care and Use 
committee (IACUC).
Euthanasia and specimen collection
Mice were euthanized at 12 weeks of age, and lower limbs and lumbar 5 vertebrae were 
dissected from these animals. The femora on the right side were immediately stored at 
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−80°C in saline-soaked gauze for subsequent biomechanical testing. The femora on the left 
side were stripped of muscle, fixed in 10% neutral buffer formalin for 48 hours before 
transferred to 70% ethyl alcohol and stored at 4°C for densitometry and histomorphometry 
analyses. In addition, after removing of muscle and periosteum, both ends of the tibia and 
humeri were cut to flush out the marrow cavity with PBS before transferring them to RNA 
later stabilization reagent (Qiagen, CA). We also harvested muscle, spleen, heart and kidney 
tissues from both WT and Dmp1-hWNT16 transgenic mice, which were flash frozen 
immediately and stored at −80°C until use for gene expression analysis.
Gene expression analysis
Measurements of gene expression were performed by real-time PCR using bone and other 
organs from both male and female WT and Dmp1-hWNT16 TG mice as described 
previously (14). All qPCR reactions were performed using the custom-made primer and 
probe sets from Integrated DNA Technology (IDT, USA) for human WNT16 (hWNT16), 
endogenous mouse Wnt16 (Wnt16), runt related transcription factor 2 (Runx2), alkaline 
phosphatase (Alp), osteocalcin (OC), osteoprotegerin (Opg) and tumor necrosis factor 
(ligand) superfamily, member 11 (Rankl or Tnfs11). We also investigated 1) Wnt signaling 
pathway canonical genes - beta-catenin (Ctnnb1) and Axin 2 (Axin2), and 2) Wnt signaling 
pathway non-canonical genes - jun proto-oncogene (c-Jun or Ap1), mitogen-activated 
protein kinase 8 (Jnk or Mapk8), protein kinase, cAMP dependent, catalytic, alpha (Pka), 
protein kinase C (Pkc). Real-time detection of PCR products was accomplished using an 
ABI PRISM 7900 sequence detector (Applied Biosystem, CA) and normalized to the house-
keeping gene beta-Actin.
Dual energy X-ray absorptiometry (DXA)
The whole body, femur and lumbar vertebrae 1 through 5 of the WT and Dmp1-hWNT16 
TG mice were scanned using DXA (PIXImus II mouse densitometer; Lunar Corp., Madison, 
WI, USA) with ultra-high resolution (0.18 × 0.18 mm/pixel) as described previously (14). 
After completion of the scan of each bone, mutually exclusive region of interest (ROI) boxes 
were drawn around the bone from which femur aBMD (g/cm2) and BMC (g) measurements 
were obtained.
Micro Computer Tomography (µCT) analysis
The femurs and lumbar 5 vertebrae of WT and Dmp1-hWNT16 TG mice were scanned with 
a high resolution µCT scanner (vivaCT 40, Scanco Medical AG, Switzerland) with an 
isotropic voxel size of 10.5 µm3 as described previously (14). In brief, from the scout-view, 
the growth plate location was identified and trabecular bone measurements consisting of 200 
slices (2.1 mm) was completed from about 1 mm below the growth plate. Lumbar 5 
vertebrae measurements included the vertebral body from the cephalad to the caudal 
endplate excluding the cortical bone. For cortical bone analysis, the mid-femur of each bone 
was determined from the scout-view and a total of 60 slices (30 slices above and 30 slices 
below the mid-femur) were scanned with the same setting as described previously (14). 
Finally, 3D and 2D morphometric evaluations were performed for the cortical and trabecular 
bone from each scan, and bone volume (BV/TV) and structural parameters (trabecular 
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number, Tb.N; trabecular thickness Tb.Th; trabecular separation, Tb.Sp; cortical bone area, 
B.Ar/T.Ar; cortical thickness, Ct.Th) were determined.
Biomechanical measurements
Three-point bending measurement of whole-bone strength of femur was performed using an 
electromechanical test machine (TestResources, MN, USA) as described previously (14). In 
brief, the femurs were held in place by small preload (<1N) and each bone was loaded to 
failure in monotonic compression using a crosshead speed of 0.2 mm/s, during which force 
and displacement measurements were collected every 0.02 s. From the force versus 
displacement curves, yield force (N), stiffness (N/mm), ultimate force (N) and energy to 
failure (mJ) were calculated using MTestWR™ software following standard equations (19).
Cortical and Trabecular bone dynamic histomorphometry
Mice were given calcein (15 mg/kg) and alizarin (30 mg/kg) intraperitoneally 10 days and 3 
days before euthanasia at 12 weeks of age. Dynamic bone formation parameters were 
calculated from the femur midshaft for cortical and distal femur secondary spongiosa for 
trabecular bone by measuring the unlabeled perimeter (nL.Pm), single-labeled perimeter 
(sL.Pm), double-labeled perimeter (dL.Pm) and the area between the double labeling 
(dL.Ar) using the Bioquant Osteo system (Bioquant Corp.) as described previously (14). 
Derived histomorphometric parameters, including mineralizing surface (MS/BS, %), mineral 
apposition rate (MAR, um/yr) and bone formation rate (BFR/BS, um3/um2/yr), were 
calculated using standard procedures recommended by the ASBMR histomorphometry 
Committee (21).
Cellular parameters
We compared osteoblast perimeter (Ob.Pm; mm), number of osteoblast (N.Ob), osteoblast 
number over osteoblast perimeter (N.Ob/Ob.Pm), osteoblast surface over bone surface 
(Ob.S/BS; %) and osteoblast number over bone perimeter (N.Oc/B.Pm) between WT and 
transgenic female mice. For osteoclast, we measured osteoclast perimeter (Oc.Pm; mm), 
osteoclast number over osteoclast perimeter (N.Oc/Oc.Pm), osteoclast surface over bone 
surface (Oc.S/BS; %) and osteoclast number over bone perimeter (N.Oc/B.Pm) in these 
mice using standard procedures recommended by the ASBMR histomorphometry 
Committee (21).
Serum biomarkers
Serum levels of mouse osteoprotegerin (OPG) and tumor necrosis factor (ligand) 
superfamily, member 11 (RANKL) were measured by Enzyme-Linked ImmunoSorbent 
Assay (ELISA) kits (R&D Systems, MN, USA) according to the manufacturers’ 
instructions. Serum levels of carboxy-terminal collagen crosslinks (CTX), tartrate-resistant 
acid phosphatase 5, isoform b (TRAcP5b) and pro-collagen 1 intact N-terminal (P1NP) were 
measured by ELISA kits (Immunodiagnostics Systems, AZ, USA and Biomedical 
Technologies Inc., MA, USA) per manufacturers’ instructions. Serum calcium (Ca), 
phosphorus (P), blood urea nitrogen (BUN), creatinine (CREA) and alkaline phosphatase 
(ALP) were measured using the Randox Rx kit (Daytona Analyzer, WV, USA).
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Statistical analysis
Quantitative data were expressed as mean ± SEM. Statistical differences between WT and 
Dmp1-hWNT16 transgenic groups were tested using the unpaired Student’s t test. Gender 
and genotype interaction was analyzed by two-way analysis of variance (ANOVA). All 
statistical analysis was performed using the statistical software package StatView (Abacus 
Concepts, Inc., Berkeley, CA). The level of significance was set at p ≤0.05.
Results
Dmp1-hWNT16 TG mice had similar body weight and femoral bone length as WT mice
Transgenic WNT16 mice were born with expected frequency and appeared healthy with no 
discernible growth or morphological defects. Compared to WT mice, transgenic WNT16 
mice showed similar body weight (g) in male and female at 6 and 12 weeks of age (Table 1). 
In addition, the femur length (mm) at 6 and 12 weeks of age did not differ between male WT 
and transgenic mice (Table 1).
Dmp1-hWNT16 TG mice expressed high levels of hWNT16 in bone tissue
We detected significantly higher (p<0.0001) levels of transgene (hWNT16) expression in 
bone tissue compared to other tissues (muscle, spleen, heart and kidney) in the transgenic 
mice in both male and female (Figure 1B). In addition, the expression of hWNT16, as 
expected, was detectable only in the transgenic mice (Figure 1B). The level of endogenous 
mouse Wnt16 mRNA expression in the bone tissue was significantly higher (p<0.0001) 
compared to other tissues (Figure 1C). In addition, Wnt16 mRNA expression was 
significantly lower (p<0.05) in the transgenic male mice compared to sex-matched WT 
littermates (Figure 1C).
Dmp1-hWNT16 TG mice exhibited higher whole body, femur and spine aBMD and BMC 
measured by DXA
Male transgenic WNT16 mice had significantly higher whole body aBMD and BMC (10% 
and 12%, respectively; p<0.05) compared to WT littermates at 6 weeks of age (Figure 2A 
and Table 1). Similarly, female transgenic mice showed 16% higher whole body aBMD and 
21% higher BMC (p<0.005) compared to female WT mice at this age. At 12 weeks of age, 
both male and female transgenic WNT16 mice had significantly higher whole body aBMD 
(9%, p<0.001 and 14%, p<0.0001; respectively) and BMC (11%, p<0.01 and 21%, 
p<0.0001; respectively) than WT littermates (Figure 2A and Table 1).
Femoral aBMD measured at 12 weeks of age showed significantly higher values for both 
transgenic male and female mice (12%, p<0.001 and 17%, p<0.0001; respectively) as 
compared to WT mice (Table 1). Similarly, femur BMC was 11% higher in male (p<0.05) 
and 15% higher in female (p<0.01) Dmp1-hWNT16 TG mice (Table 1). Spine DXA was 
measured for lumbar 1 through 5 vertebrae at 12 weeks of age. The spine aBMD in 
transgenic mice was 14% higher (p<0.001) in male and 20% higher (p<0.0001) in female 
compared to WT mice (Figure 2B and Table 1). Similarly, spine BMC was 15% higher in 
male (p<0.05) and 26% higher in female (p<0.0001) Dmp1-hWNT16 TG mice (Table 1).
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Dmp1-hWNT16 TG mice displayed higher bone mass and improved micro-architecture in 
cancellous and cortical bone measured by µCT
To further identify the effects of the hWNT16 transgene on skeletal properties in greater 
detail, we measured bone mass and micro-architectural properties in the distal femur and 
lumbar 5 vertebra for cancellous bone and at the femoral midshaft for the cortical bone in 
12-week-old mice using µCT. Male Dmp1-hWNT16 transgenic mice displayed 2-fold higher 
(p<0.0005) trabecular BV/TV whereas female transgenic mice exhibited 5-fold increase 
(p<0.0001) in BV/TV at distal femur compared to their WT littermates (Figures 3A & 3B). 
Male Dmp1-hWNT16 TG mice also showed 29% higher Tb.N (p<0.001) and 21% higher 
Tb.Th (p<0.001) and 23% lower Tb.Sp (p<0.005) whereas female Dmp1-hWNT16 TG mice 
exhibited 50% higher Tb.N (p<0.0001) and 50% higher Tb.Th (p<0.0001) and 35% lower 
Tb.Sp (p<0.0001) at the same site (Figures 3A & 3B). Cortical bone morphometry at mid-
femur revealed that male Dmp1-hWNT16 TG mice had 11% higher B.Ar/T.Ar (p<0.05) and 
4% higher Ct.Th (p<0.005) whereas female transgenic mice exhibited 10% higher B.Ar/T.Ar 
(p<0.0001) and 6% higher Ct.Th (p<0.0005) compared to sex-matched WT mice (Figures 
4A & 4B). At lumbar 5 vertebra, male Dmp1-hWNT16 transgenic mice displayed 44% 
higher (p<0.001) trabecular BV/TV whereas female transgenic mice exhibited 122% higher 
(p<0.0001) in BV/TV compared to their WT littermates (Figures 5A). Male Dmp1-hWNT16 
TG mice also showed 18% higher Tb.N (p<0.005) and 19% higher Tb.Th (p<0.005) and 
15% lower Tb.Sp (p<0.005) whereas female Dmp1-hWNT16 TG mice exhibited 42% higher 
Tb.N (p<0.0001) and 39% higher Tb.Th (p<0.0001) and 29% lower Tb.Sp (p<0.0001) at the 
same site (Figures 5B–5D). Two-way ANOVA (gender and genotype interaction) analysis 
showed sex-specific differences for trabecular (p<0.005) bone phenotypes both at distal 
femur and lumbar 5 vertebra in the Dmp1-hWNT16 TG mice. Overall, these data indicate 
that while no differences were observed between male and female Dmp1-hWNT16 TG mice 
in the cortical compartment, female transgenic mice displayed a more pronounced effect of 
the transgene than did male mice in the cancellous compartment.
Serum markers of bone formation and resorption are not significantly influenced in Dmp1-
hWNT16 TG mice
To understand potential changes in serum biochemistry induced by transgenic 
overexpression of WNT16 in bone, we measured biomarkers related to skeletal metabolism 
in serum samples collected from 12-week-old mice. Dmp1-hWNT16 TG mice showed 
similar levels of calcium, phosphorus, BUN and creatinine compared to their WT littermates 
in both male and female (Table 2). Two serum markers of bone formation, ALP and P1NP, 
did not differ significantly between the WT and Dmp1-hWNT16 TG in both sexes. In 
addition, we detected similar levels of serum OPG and RANKL for both genotypes in male 
and female mice. Further, serum bone resorption markers CTX, TRAcP5b and CTX/
TRAcP5b levels did not differ significantly in the transgenic mice compared to WT mice in 
both sexes (Table 2).
Biomechanical properties of femoral diaphysis are improved in Dmp1-hWNT16 TG mice
To identify whether the higher bone mass and better micro-architecture in Dmp1-hWNT16 
mice were associated with improvements in mechanical properties of the skeleton, we tested 
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femurs from Dmp1-hWNT16 TG and WT mice using monotonic 3-point bending tests. 
Female Dmp1-hWNT16 TG mice had significantly higher yield force (10%; p=0.01), 
stiffness (11%; p=0.01), ultimate force (17%; p=0.006) and energy to ultimate force (35%; 
p=0.02) as compared to female WT mice (Figure 6). In contrast, male Dmp1-hWNT16 TG 
mice exhibited similar values for stiffness, ultimate force and energy to ultimate force 
compared to sex-matched WT mice (Figure 6).
Trabecular bone formation rate, mineral apposition rate and mineralizing surface are 
significantly increased by hWNT16 overexpression in female Dmp1-hWNT16 TG mice
To determine whether greater cortical and trabecular bone volume in Dmp1-hWNT16 TG 
mice was driven by enhanced bone formation, we measured dynamic bone formation 
parameters in the femur midshaft and distal femur secondary spongiosa using fluorochrome 
labels embedded in the bone prior to sacrifice at 12 weeks of age. We compared 
mineralizing surface (MS/BS), mineral apposition rate (MAR) and bone formation rate 
(BFR/BS) between sex-matched WT and Dmp1-hWNT16 TG mice. Both male and female 
transgenic mice had significantly higher MS/BS (22%, p<0.05 and 192%, p<0.0005; 
respectively) than their sex-matched WT littermates in the distal femur (Figure 7A). Female 
transgenic mice also had 28% higher MAR (p<0.01) compared to WT female littermates 
(Figure 7B). In addition, BFR/BS in female transgenic mice were significantly higher 
(285%; p<0.0005) than in sex-matched control WT mice (Figure 7C). In femur midshaft, 
male and female Dmp1-hWNT16 transgenic mice displayed similar values for periosteal 
MS/BS, MAR and BFR/BS compared to sex-matched WT littermates (Figure 7D–F). In 
addition, endosteal MS/BS, MAR and BFR/BS values in transgenic mice did not differ from 
WT control mice in both sexes (data not shown).
Higher expression of bone formation related genes are observed in the transgenic mice
Significantly higher mRNA levels of Alp (64% in male and 3-fold in female; p<0.05) and a 
non-significant higher levels of Runx2 (22% in male and 59% in female; p=0.1) were 
observed in the long bone of the transgenic mice compared to their WT littermates (Figure 
8A and 8B). The level of Osteocalcin expression was significantly higher (84%; p<0.05) in 
male and 37% higher in female transgenic mice (Figure 8C). In addition, 3-fold higher 
expression of Opg and 2-fold higher expression of Rankl were detected in the transgenic 
mice compared to WT mice (Figure 8D and 8E) in male. The levels of Ctnnb1 expression 
was 52% higher in the male transgenic mice compared to male WT littermates (Figure 8F). 
In addition, mRNA expression levels of c-Jun/Ap1, Jnk/Mapk8, Pka and Pkc did not differ 
between the WT and Dmp1-hWNT16 TG mice in both male and female (data not shown).
Osteoblast and osteoclast number and surface area are not significantly changed by 
hWNT16 overexpression
Transgenic female mice displayed similar values for N.Ob, Ob.Pm, N.Ob/B.Pm and 
Ob.S/BS compared to sex-matched WT mice (Supplemental Figure 1A–C). In addition, 
N.Oc, Oc.Pm, N.Oc/B.Pm and Oc.S/BS did not differ between two genotypes (Supplemental 
Figure 1A, 1B and 1D).
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Discussion
The goal of this study was to identify the role of osteocyte-specific overexpression of human 
WNT16 on bone phenotypes in growing and adult mice. We detected significantly higher 
whole-body and site-specific (femur and spine) aBMD and BMC, and major improvement of 
micro-architectural properties of cancellous and cortical bone in the femur in both male and 
female transgenic mice. In addition, we found a milder cortical bone phenotype and a superb 
cancellous bone phenotype in transgenic mice in both sexes. Further, striking sex-specific 
phenotypic differences were observed in the transgenic mice, with more pronounced effect 
of the transgene in female mice in cancellous bone and substantial improvement of bone 
biomechanical properties in female, compared to male transgenic mice. Together, these 
results suggest that WNT16 has a marked positive effect for regulation of both cortical and 
trabecular bone mass and strength.
Both growing and adult Dmp1-hWNT16 TG mice displayed similar body weight and femur 
length as compared to WT mice, however, phenotypic differences for aBMD and BMC were 
clearly noticeable as early as 4 weeks of age between the two genotypes. Additionally, 
values for DXA and microCT derived bone phenotypes in transgenic mice were superior at 
both axial (lumbar spine) and appendicular (femur) skeletal sites compared to their WT 
counterparts. Bone phenotypes were also more pronounced in females and the phenotypic 
differences between wild-type and transgenic mice were maintained to the adult age. Sex-
specific differences between Dmp1-hWNT16 TG mice were also observed in the femur 
three-point bending test and bone histomorphometric measurements. Female Dmp1-
hWNT16 TG displayed superior biomechanical properties of femur and substantial 
improvement of dynamic bone formation parameters at the trabecular site compared to male 
transgenic mice.
Compared to our previous osteoblast-specific overexpression of WNT16 study (14) and 
another study using similar mouse model (15), the current study showed that osteocyte-
specific overexpression of WNT16 increased similar extent of aBMD in whole body and 
spine, however, we observed lower magnitude of trabecular BV/TV increase at distal femur 
in both male and female Dmp1-hWNT16 transgenic mice. This could be due to transgene 
expression differences in osteocytes versus osteoblasts at this skeletal site in these mouse 
models. Also, mouse Wnt16 mRNA was decreased only in the male Dmp1-hWNT16 
transgenic bone compared to WT bone, suggesting that transgenic mice might process 
endogenous Wnt16 mRNA differently. In addition, in the male Col2.3-WNT16 transgenic 
mice, expression of Opg in bone tissue was significantly increased whereas no changes were 
observed in the Rankl expression leading to higher Opg/Rankl ratio in the transgenic mice 
(14). In contrast, while mRNA level of Opg was increased 3-fold, expression of Rankl was 
also increased 2-fold in the male Dmp1-hWNT16 transgenic mice, resulting in no changes 
of Opg/Rankl ratio in the transgenic mice compared to sex-matched wild-type mice, 
suggesting a higher level of bone turnover in the transgenic mice. Further, while the N.Oc/
B.Pm and Oc.S/BS were significantly lower in the Col2.3-WNT16 transgenic mice (14), 
these values were similar in the Dmp1-hWNT16 transgenic mice compared to sex-matched 
wild-type mice. On the other hand, Movérare-Skrtic S. et al. found no significant changes of 
bone formation or resorption markers in mice overexpressing WNT16 in osteoblasts (15). 
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These discrepancies might be related to the different levels of transgenes produced by 
osteoblasts and osteocytes as well as the type of interactions, for example, paracrine or 
autocrine, among these bone cells with osteoclasts and other cells in the bone tissue. Our 
finding in the current study is in agreement with a previous study demonstrating that the 
periosteal BFR and MAR were significantly reduced in female Wnt16 knockout mice 
compared to wild-type mice at 12 weeks of age (12). However, in another study (13), a non-
significant trend of lower periosteal MAR at 6 weeks of age and no changes of periosteal 
MAR at 12 weeks of age was observed in Wnt16 knockout mice, which could be due to the 
different bones (tibia versus femur) used for histomorphometric measurements.
Striking differences of bone phenotypes detected between male and female in the WNT16 
transgenic mice were in concert with those observed in the Wnt16 knockout mice. Several 
studies demonstrated that global deletion of Wnt16 in female mice decreased cortical bone 
volume and thickness, increased cortical porosity, and resulted in spontaneous fractures at 
multiple skeletal sites (7, 8, 13). Recently, conditional deletion of Wnt16 from osteoblast-
lineage cells also revealed that Wnt16 is a critical regulator for maintenance of cortical bone 
mass and fracture susceptibility in female mice (13). In addition, female Wnt16 knockout 
mice failed to increase periosteal bone formation in response to mechanical loading (12). 
This sex-specific bone phenotype differences were also observed in Col2.3-WNT16 (14) and 
Dmp1-hWNT16 transgenic mice. In concert, Movérare-Skrtic S. et al., recently 
demonstrated that osteoblast-specific overexpression of mouse Wnt16 predominantly 
increased trabecular bone mass in female mice (15). Together, these results strongly suggest 
the potential role of sex-hormones mediating the effect of Wnt16 transgene for bone 
homeostasis. Recently, using two genetically modified mouse models (Wnt16 knockout and 
osteoblast-specific Wnt16 overexpression), Movérare-Skrtic S. et al., demonstrated that 
although Wnt16 mRNA expression is enhanced by estradiol treatment, the bone-sparing 
effects of estrogen and WNT16 are independent of each other (15). In addition, Todd H. et 
al., found that estrogen deficiency or ovariectomy decreased expression of Wnt16 whereas 
estrogen replacement using 17b-estradiol and the Selective Estrogen Receptor Modulator 
Tamoxifen increased expression of Wnt16 in the cortical bone in mice (16), suggesting 
potential interactions between Wnt16 and estrogen for overall bone mass regulation. Further 
studies are thus necessary to decipher the complex interplay between estrogen and Wnt16 
for regulation of bone homeostasis.
The WNT signaling pathway plays a major role in embryonic development and postnatal 
health and diseases, including bone and mineral homeostasis (17–20). Studies involving both 
global and conditional deletion of Wnt16 from osteoblast-lineage cells in mice revealed that 
Wnt16 is a critical regulator for maintenance of cortical bone mass and fracture 
susceptibility (7, 8, 13). In a previous study, we observed a robust trabecular bone phenotype 
in the Col2.3-WNT16 transgenic (overexpressing human WNT16 in osteoblasts) mice in 
both males and females (14). More recently, Movérare-Skrtic S. et al., demonstrated that 
osteoblast-specific overexpression of mouse Wnt16 predominantly increased trabecular bone 
mass in female mice at 16 weeks of age (15). In the current study, we further observed 
superb cancellous bone phenotype in male and female Dmp1-hWNT16 transgenic mice. 
This drastic difference of cortical bone phenotypes in the Wnt16 knockout mouse models 
(global and conditional) versus predominant trabecular bone phenotypes in the Dmp1-
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hWNT16 (current study) and Col2.3-WNT16 (14) overexpression mouse models might 
result from various factors including 1) interactions of complex signaling among several 
Wnts and their intracellular and extracellular modulators, 2) differences in bone micro-
environment, 3) influences of mechanical signals perceived by the tissue, and 4) cross-talk 
of Wnt signaling with other signaling pathways. In addition, levels of endogenous Wnt16 
mRNA expression might vary between cortical and trabecular bone as it has been shown 
previously (15). This could lead to different dose-response curves proposed recently 
between Wnt16 expression and bone mass in these two compartments (15). These results are 
in consistent with previous human GWAS studies demonstrating the association between 
WNT16 and BMD at skeletal sites with predominant trabecular bone such as spine and heel 
(5, 10, 11). Overall these data suggest that WNT16 exerts distinct effect on compartment-
specific bone mass, depending on whether it is perturbed physiologically (knockout of 
Wnt16) or manipulated pharmacologically (overexpression of WNT16). Up-regulation of 
Wnt16 as a pharmacological approach may therefore have great potential for treating 
conditions with substantial trabecular bone loss such as post-menopausal osteoporosis and 
glucocorticoid induced bone loss.
This study has several limitations. We did not measure bone phenotypes in mice older than 
12 weeks of age, therefore, whether the transgenic mice will preserve higher bone mass and 
strength as they age needs to be explored in future. Also, we have not investigated the effect 
of mechanical loading or unloading on bone phenotypes in our transgenic mouse model. 
Moreover, as strong sex-specific differences were observed in the transgenic mice, whether 
and how sex hormones contribute to the overall bone homeostasis in these mice needs 
further investigation.
In conclusion, we demonstrated that Dmp1-hWNT16 transgenic mice exhibited significantly 
higher total body, spine and femoral bone mineral density in both male and female mice. 
Bone volume and micro-architecture at trabecular sites were also significantly improved in 
the transgenic mice, particularly in female. Cortical bone areas and thickness were modestly 
improved in the transgenic mice in both sexes, and bone biomechanics was substantially 
improved in the female transgenic mice. Our data indicate that WNT16 is critical for the 
acquisition of both cortical and trabecular bone mass and strength, and that this molecule 
might be targeted for therapeutic interventions to treat osteoporosis or other low bone mass 
and high bone-fragility conditions.
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Fig. 1. 
Generation and characterization of the Dmp1-hWNT16 transgenic mice. The human 
WNT16 (hWNT16) cDNA was cloned into the pBluescript II KS plasmid (pBS-KS) 
between the osteocyte-specific Dmp1 promoter (8 kb of the 5’-flanking region, the first 
exon, the first intron and 17 bp of exon2 of the murine Dmp1 gene, a kind gift from Teresita 
Bellido) and rabbit beta-globin polyA signal (1A). Higher level of transgene (hWNT16) was 
observed in bone tissue compared to other tissues (muscle, spleen, heart and kidney) in 
transgenic mice measured by real-time PCR (1B). A high level of transgene (hWNT16) 
mRNA expression was detected only in the transgenic mice (1B). The level of endogenous 
mouse Wnt16 mRNA expression in the bone tissue was significantly higher compared to 
other tissues (1C). Values are given as mean ± SEM *p<0.0001 vs. corresponding WT using 
Student’s t test. WT: wild-type; TG: Dmp1-hWNT16 transgenic
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Fig. 2. 
Whole body and spine (L1–5) aBMD measured by DXA. Both male and female transgenic 
Dmp1-hWNT16 transgenic mice exhibited significantly higher whole body (2A) and spine 
(2B) aBMD at 6 and 12 weeks of age compared to age- and sex-matched WT mice. Values 
are given as mean ± SEM *p<0.05; **p<0.0005; ***p<0.0001 vs. corresponding WT using 
Student’s t test. WT: wild-type; TG: Dmp1-hWNT16 transgenic
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Fig. 3. 
Trabecular bone morphometry measured by micro-CT. Representative µCT pictures at distal 
femur in male and female WT and Dmp1-hWNT16 transgenic mice (3A). Compared to WT 
mice, Dmp1-hWNT16 transgenic mice at 12 weeks of age showed significantly higher 
trabecular bone volume (BV/TV), trabecular number (Tb.N) and trabecular thickness 
(Tb.Th), but significantly lower trabecular separation (Tb.Sp) at distal femur in both male 
and female (3B). Values are given as mean ± SEM *p<0.05; **p<0.0005; ***p<0.0001 vs. 
corresponding WT using Student’s t test. WT: wild-type; TG: Dmp1-hWNT16 transgenic
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Fig. 4. 
Cortical bone morphometry measured by micro-CT. Representative µCT pictures at femur 
midshaft in male and female WT and Dmp1-hWNT16 transgenic mice (4A). Male and 
female Dmp1-hWNT16 transgenic mice showed significantly higher cortical bone area 
(B.Ar/T.A) and cortical thickness (Ct.Th) compared to their sex-matched WT littermates at 
12 weeks of age (4B). Values are given as mean ± SEM *p<0.05; **p<0.0005; ***p<0.0001 
vs. corresponding WT using Student’s t test. WT: wild-type; TG: Dmp1-hWNT16 
transgenic
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Fig. 5. 
Trabecular bone morphometry at lumbar 5 vertebra measured by micro-CT. Compared to 
WT mice, Dmp1-hWNT16 transgenic mice at 12 weeks of age showed significantly higher 
trabecular bone volume (BV/TV) (5A), trabecular number (Tb.N) (5B) and trabecular 
thickness (Tb.Th) (5C), but significantly lower trabecular separation (Tb.Sp) (5D) at lumbar 
5 vertebra in both male and female. N=6 per sex per genotype. Values are given as mean ± 
SEM **p<0.005; ***p<0.0001 vs. corresponding WT using Student’s t test. WT: wild-type; 
TG: Dmp1-hWNT16 transgenic
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Fig. 6. 
Measurement of bone strength by femur biomechanical test. Three-point bending test of 
femora from 12-wk-old mice demonstrated that female Dmp1-hWNT16 transgenic mice 
showed significantly higher yield force (6A), stiffness (6B), ultimate force (6C) and energy 
to ultimate force (6D) as compared to female WT mice. In contrast, male Dmp1-hWNT16 
TG mice exhibited similar values for stiffness, ultimate force and energy to ultimate force 
compared to sex-matched WT mice. Values are given as mean ± SEM vs. *p<0.05 
corresponding WT using Student’s t test. WT: wild-type; TG: Dmp1-hWNT16 transgenic
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Fig. 7. 
Dynamic trabecular and cortical bone histormorphometric measurements. Fluorochrome 
labeling of trabecular bone from 12-wk-old mice revealed that both male and female Dmp1-
hWNT16 transgenic mice had significantly higher distal femur MS/BS compared to WT 
mice (7A). Female Dmp1-hWNT16 transgenic mice also showed significantly higher MAR 
(7B) and BFR/BS (7C) compared to sex-matched WT littermates. In femur midshaft, male 
and female Dmp1-hWNT16 transgenic mice displayed similar values for periosteal MS/BS, 
MAR and BFR/BS compared to sex-matched WT littermates (7D–F). Values are given as 
mean ± SEM *p<0.005; **p<0.0005 vs. corresponding WT using Student’s t test. WT: wild-
type; TG: Dmp1-hWNT16 transgenic
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Fig. 8. 
Analyses of gene expression in the bone tissue. The mRNA levels of Alp was significantly 
higher in the bone tissue of both male and female Dmp1-hWNT16 transgenic mice 
compared to the sex-matched WT littermates (8B). The level of Osteocalcin expression was 
significantly higher in male Dmp1-hWNT16 transgenic mice (8C). In addition, expression 
of Opg and Rankl were significantly up-regulated in the same tissue in male Dmp1-
hWNT16 transgenic mice (8D and 8E) compared to the WT littermates. N=5–6 per sex per 
genotype. Values are given as mean ± SEM vs. *p<0.05 corresponding WT using Student’s t 
test. WT: wild-type; TG: Dmp1-hWNT16 transgenic
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